C-RAD announced today that it signed a purchasing agreement with MedAustron – the first Ion-therapy treatment site in Austria. The agreement entails the acquisition of C-RAD’s most advanced surface tracking technology and a service agreement.
C-RAD offers a specific version of its Catalyst System for use in proton and particle therapy – Catalyst PT. It is based on the patented Catalyst technology and software as well as the hardware are tailored for the application in this environment. MedAustron went through a public procurement process and at its end the tender was awarded to C-RAD.
The installation of the C-RAD motion management solution will follow a phased approach, whereas the Catalyst PT system will be installed in one of the treatment rooms in the first stage. In further steps the system will be integrated into the existing treatment control system to optimize workflows and usability within particle therapy. The solution that is going to be delivered to MedAustron is a platform, that allows customers to seamlessly integrate motion management into particle treatment systems from various providers and vendors.
Priv. Doz. DI Markus Stock, PhD, Head of Medical Physics at MedAustron adds:
“Strategies for coping with organ motions are crucial for a successful irradiation of certain tumor entities. Whereas our in-room equipment already features precise positioning, position verification and monitoring, the implementation of Catalyst PT will enhance our system significantly by expanding it with tools for motion management.“
MedAustron, the center for ion therapy and research is located in Wiener Neustadt in Lower Austria, about 50 kilometers south of Vienna. It is the first center for particle therapy in Austria, and currently treats patients using a proton beam. Besides clinical operation, also non-clinical research in the areas of radiation oncology, medical physics and radiation biology is conducted at MedAustron.
Prof. Dr. Eugen B. Hug, clinical director co-managing director of MedAustron, says: “We look forward to addressing the issue of organ motion management together with C-RAD. The decision was made in favor of their Catalyst PT system, because they best met our requirements and because they demonstrated flexibility with regard to the development of customized features.”
As the workflows that are develop for the application can be deployed on a broad scale to customers in the fast-growing particle therapy segment, this project brings future value for C-RAD.
